Overall, our study demonstrates that SRC signaling is at the nexus of a cell-autonomous inflammatory program with pro-tumorigenic activities, which explains why BRAFV600E colorectal tumors develop resistance to BRAF/MEK and EGFR inhibitors. The gene discussed is BRAF; the disease is colorectal neoplasm.